Copyright
©The Author(s) 2021.
World J Hepatol. Sep 27, 2021; 13(9): 1154-1166
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1154
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1154
Disorder | Biomarker changes | Ref. |
Liver steatosis | ↓ Liver mass, ↓ content of triglycerides, free fatty acids, and cholesterol in the liver tissues | [50-52,54] |
Liver inflammation | ↓ Myeloperoxidase activity, expression of tumor necrosis factor alpha gene and neutrophil infiltration in the liver | [54] |
Oxidative stress in liver | ↓ Level of nitric oxide and malondialdehyde and ↑ level of glutathione and catalase in the liver tissue | [50,51,54] |
Death of hepatocytes | ↓ Serum aminotransferases | [50-54] |
Systemic inflammation | ↓ Serum IL-6 and tumor necrosis factor alpha | [51-53] |
Bacterial translocation | ↓ Serum lipopolysaccharide | [51-54] |
Gut dysbiosis | ↑ Firmicutes, Clostridiales and Lactobacillales; ↓ Proteobacteria and Campylobacterales | [51,53] |
Damage to the intestinal epithelium | ↓ Serum diamine oxidase | [53] |
Increased intestinal permeability | ↓ Serum D-lactate, ↑ the amount of occludin and other protein of tight junction in the gut epithelium, ↓ intestinal permeability for dyes | [50,52-54] |
Dyslipidemia | ↓ Serum cholesterol and triglycerides | [50,52-54] |
- Citation: Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Probiotics in hepatology: An update. World J Hepatol 2021; 13(9): 1154-1166
- URL: https://www.wjgnet.com/1948-5182/full/v13/i9/1154.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i9.1154